Cowley, United Kingdom

Gilles Denis Pain

USPTO Granted Patents = 3 

Average Co-Inventor Count = 4.0

ph-index = 1


Location History:

  • Cowley, GB (2005 - 2007)
  • Oxford, GB (2007)

Company Filing History:


Years Active: 2005-2007

Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Gilles Denis Pain

Introduction

Gilles Denis Pain is a notable inventor based in Cowley, GB. He has made significant contributions to the field of antibacterial agents, holding a total of 3 patents. His work focuses on developing compounds that can effectively combat microbial infections.

Latest Patents

Gilles Denis Pain's latest patents include innovative antibacterial agents. One of his notable inventions involves compounds of formula (II) that serve as antibacterial agents, where Q represents a radical of specific formulas. These compounds are designed to target various bacterial infections effectively. Another significant patent involves N-formyl hydroxylamine derivatives, which act as inhibitors of bacterial polypeptide formylase. This invention aims to treat infections in both humans and non-human mammals, showcasing his commitment to advancing medical science.

Career Highlights

Gilles Denis Pain is associated with British Biotech Pharmaceuticals Limited, where he continues to contribute to groundbreaking research in pharmaceuticals. His work has been instrumental in developing new treatments that address pressing health concerns.

Collaborations

Throughout his career, Gilles has collaborated with esteemed colleagues, including Lisa Marie Pratt and Kenneth Noel Keavey. These partnerships have fostered an environment of innovation and creativity, leading to the development of effective antibacterial solutions.

Conclusion

Gilles Denis Pain's contributions to the field of antibacterial agents highlight his dedication to improving health outcomes through innovative research. His patents reflect a commitment to addressing microbial infections, making a significant impact in the pharmaceutical industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…